Free Trial
NASDAQ:NRXS

NeurAxis (NRXS) Stock Price, News & Analysis

NeurAxis logo
$2.24 -0.11 (-4.72%)
Closing price 03:59 PM Eastern
Extended Trading
$2.11 -0.13 (-5.58%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeurAxis Stock (NASDAQ:NRXS)

Key Stats

Today's Range
$2.20
$2.31
50-Day Range
$1.62
$2.44
52-Week Range
$1.33
$3.78
Volume
3,282 shs
Average Volume
17,830 shs
Market Capitalization
$16.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Receive NRXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter.

NRXS Stock News Headlines

NeurAxis (NASDAQ:NRXS) Trading 10.3% Higher - Time to Buy?
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
See More Headlines

NRXS Stock Analysis - Frequently Asked Questions

NeurAxis' stock was trading at $2.35 at the beginning of the year. Since then, NRXS stock has decreased by 4.9% and is now trading at $2.2340.
View the best growth stocks for 2025 here
.

NeurAxis, Inc. (NASDAQ:NRXS) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter. The firm earned $0.67 million during the quarter.

NeurAxis (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share.

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), AMMO (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI).

Company Calendar

Last Earnings
11/12/2024
Today
5/01/2025
Next Earnings (Estimated)
5/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical equipment
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NRXS
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,630,000.00
Net Margins
-492.76%
Pretax Margin
-341.35%

Debt

Sales & Book Value

Annual Sales
$2.69 million
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
-8.27

Miscellaneous

Free Float
6,085,000
Market Cap
$16.12 million
Optionable
Not Optionable
Beta
3.46
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:NRXS) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners